As reported by Healio Rheumatology, investigators of a newly published study in the Journal of Rheumatology found the use of antimalarials reduced the risk of serious infections in patients with systemic lupus erythematosus.
Using data from the Kaiser Permanente Medical Care Program, Northern California, Lisa J. Herrinton, PhD and colleagues performed a new-user study and identified 3,030 patients with systemic lupus erythematosus (SLE). Investigators compared the risk for serious infections in patients with SLE who were either new users to glucocorticoids (GCs), antimalarials (AMs) or a combination of both therapies.
“Many patients with systemic lupus take hydroxychloroquine, which presents low risks of complications,” Dr. Herrinton, told Healio.com/Rheumatology. “The study strengthens the evidence that use of hydroxychloroquine may be beneficial for lowering the risk of infections.”